ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)
نویسندگان
چکیده
منابع مشابه
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including proteasome inhibitors, αCD38 monoclonal antibodies, as well as histone deacetylase (HDAC) inhibitors for combination therapy. HDAC inhibitors b...
متن کاملPreclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM. In the present study, we investigated the preclinical activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM....
متن کاملA third-generation IMiD for MM.
Over the past decade, increasing use of the immunomodulatory derivatives (IMiDs) thalidomide and lenalidomide and the first-inclass proteasome inhibitor bortezomib has dramatically changed the natural history of multiple myeloma (MM).2 Novel agents, initially approved for the treatment of relapsed or refractory (rel/refr) MM, are actually used up-front as part of induction therapy for both tran...
متن کاملLYMPHOID NEOPLASIA Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
1Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA; 2Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 3Lurie Family Imaging Center and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 4Acetylon Pharmaceuticals, Boston, MA, 5Center for Systems Biology, Massachusetts General Hospital, B...
متن کاملSelective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus current nonselective HDAC inhibitor drug candidates due to reduced potency against Class I HDACs ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2015
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v126.23.3040.3040